
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Primary Industry
Source
Bristol-Myers Squibb Company (NYSE:BMY)
Pharmaceuticals
Repare Therapeutics Inc. (NasdaqGS:RPTX) 2023 Form 10-K
Business Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
F. Hoffmann-La Roche Ltd
Biotechnology
Repare Therapeutics Inc. (NasdaqGS:RPTX) 2023 Form 10-K
Business Description: F. Hoffmann-La Roche Ltd, a biotechnology company, discovers and develops in-vitro diagnostics and medicines for patients worldwide. The company engages in the discovery, development, and manufacturing of in-vitro tests for the diagnosis of various diseases, including cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; development and manufacturing of diagnostic instruments; and development of a portfolio of digital solutions for laboratories, physicians, and patients. It also provides pharmaceutical products for the treatment of anemia, cancer, dermatology, hemophilia, infectious diseases, inflammatory and autoimmune diseases, neurological disorders, ophthalmology, and respiratory disorders, as well as products for the prevention of organ rejection in patients receiving kidney, heart, or liver transplants. The company was founded in 1896 and is based in Basel, Switzerland. F. Hoffmann-La Roche Ltd operates as a subsidiary of Roche Holding AG.
Hoffmann-La Roche Inc.
Pharmaceuticals
Repare Therapeutics Inc. (NasdaqGS:RPTX) 2023 Form 10-K
Business Description: Hoffmann-La Roche Inc. manufactures drugs and vitamin products. It offers drugs and in-vitro diagnostics for cancer and transplantation, and therapeutic products for cancer, neuroscience, infectious diseases, immunology, cardiovascular, and metabolism diseases. The company was formerly known as Roche Chemical Works Inc. and changed its name to Hoffmann-La Roche Inc. in January 1929. The company was founded in 1905 and is based in Little Falls, New Jersey. Hoffmann-La Roche Inc. operates as a subsidiary of Roche Holding AG.
Ono Pharmaceutical Co., Ltd. (TSE:4528)
Pharmaceuticals
Repare Therapeutics Inc. (NasdaqGS:RPTX) 2023 Form 10-K
Business Description: Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs. The company was founded in 1717 and is headquartered in Osaka, Japan.
The University of Texas M. D. Anderson Cancer Center
Health Care Facilities
Repare Therapeutics Inc. (NasdaqGS:RPTX) 2023 Form 10-K
Business Description: The University of Texas M. D. Anderson Cancer Center operates a healthcare specialty center, which provides cancer patient care, research, education, and prevention services. The company offers prevention and screening, including breast cancer screening, cervical cancer screening, colorectal cancer screening exams, endometrial cancer screening exams, liver cancer screening exams, lung cancer screening exams, mobile mammography, ovarian cancer screening exams, prostate cancer screening exams, skin cancer screening exams, women's screening exams, and men's screening exams; cancer research services in the areas of basic science, translational research, clinical research, and prevention and personalized risk assessment; clinical trials to test new treatments for both common and rare cancers; and research-driven cancer care and comprehensive educational programs that include undergraduate degrees, professional education, clinical and research training, and advanced nursing education to enable the next generation to join the fight to end cancer. The company has strategic collaboration with Federation Bio to design and manufacture a synthetic microbial consortium immunotherapy to treat cancer patients. The University of Texas M. D. Anderson Cancer Center was formerly known as The University of Texas System Cancer Center and changed its name to The University of Texas M. D. Anderson Cancer Center in 1988. The company was founded in 1941 and is based in Houston, Texas with additional locations in Conroe, League City, and Sugar Land, Texas. The University of Texas M. D. Anderson Cancer Center operates as a subsidiary of The University of Texas System.
*denotes proprietary relationship